in it to win it

InnovationMap reveals the winners of our inaugural awards

The inaugural InnovationMap Awards revealed its big winners across eight categories and honored its Trailblazer Award recipient. Photos courtesy

The votes are in — and it's time to announce the winners of the inaugural InnovationMap Awards, presented by Techwave.

The event, held September 8 at The Cannon, honored all 28 finalists, spanning innovative Houston companies and founders, as well as our first-ever Trailblazer Award recipient, Barbara Burger. Click here to read about all the finalists.

Eight judges evaluated over 100 applications across eight categories for the 2021 InnovationMap Awards presented by Techwave. This year's judges included: JulianaGaraizar, head of the Houston incubator and vice president of innovation at Greentown Labs; Alex Gras, managing director at The Cannon; Rajasekhar Gummadapu, co-founder and CEO of Techwave; Natalie Harms, editor of InnovationMap; Serafina Lalany, interim president at Houston Exponential; Jon Nordby, managing director at MassChallenge; Emily Reiser, senior manager of innovation community engagement at the Texas Medical Center; and Grace Rodriguez, CEO and executive director of Impact Hub Houston.

Want to watch the event in full? Click here.

Without further adieu, here are our 2021 InnovationMap Award winners.

Hello Alice is a small business owner's passport through entrepreneurship that helps with networking, raising capital, and accessing growth tools. The company was also nominated for the People's Choice: Startup of the Year Award and the Female-Founded Business categories.

Topl is an impact monetization engine that enables digital and sustainable transformation across value chains and empowers the monetization of impact verified on the Topl Blockchain. The company was also nominated for the People's Choice: Startup of the Year Award.

Saranas is the creator of the Early Bird, the first and only FDA-approved bleed detection system for endovascular procedures.

Nanotech is a material science company with a mission to fireproof the world and reduce energy consumption. Nanotech was also a finalist for the People's Choice category.

Mainline is an esports tournament management system, tournament organizer, and event production company.

Cemvita Factory — engineering microbes that eat CO2 and produce valuable chemicals. The company was also a finalist in the Energy Transition Business category.

Kim Roxie of LAMIK Beauty — a tech-enabled clean color cosmetics company focusing on women of all diverse backgrounds. LAMIK was also a finalist in the BIPOC-Founded Business category,

The inaugural InnovationMap Awards event, which is about three weeks away, was created to honor the best of Houston innovation. The Trailblazer Award in particular was established to honor a Houston innovation leader and advocate who's making a lasting impact on the Houston innovation community.

Barbara Burger, vice president of innovation at Chevron and president of Chevron Technology Ventures, was selected to receive the 2021 Trailblazer Award at the InnovationMap Awards presented by Techwave. Burger was nominated and approved by this year's judges. Click here to read more about the Trailblazer Award.

And the winner is.... Cheers Health, which is creating products that are designed to support your liver and help you feel better after consuming alcohol.

Trending News

 
 

Promoted

A research team housed out of the newly launched Rice Biotech Launch Pad received funding to scale tech that could slash cancer deaths in half. Photo via Rice University

A research funding agency has deployed capital into a team at Rice University that's working to develop a technology that could cut cancer-related deaths in half.

Rice researchers received $45 million from the National Institutes of Health's Advanced Research Projects Agency for Health, or ARPA-H, to scale up development of a sense-and-respond implant technology. Rice bioengineer Omid Veiseh leads the team developing the technology as principal investigator.

“Instead of tethering patients to hospital beds, IV bags and external monitors, we’ll use a minimally invasive procedure to implant a small device that continuously monitors their cancer and adjusts their immunotherapy dose in real time,” he says in a news release. “This kind of ‘closed-loop therapy’ has been used for managing diabetes, where you have a glucose monitor that continuously talks to an insulin pump. But for cancer immunotherapy, it’s revolutionary.”

Joining Veiseh on the 19-person research project named THOR, which stands for “targeted hybrid oncotherapeutic regulation,” is Amir Jazaeri, co-PI and professor of gynecologic oncology at the University of Texas MD Anderson Cancer Center. The device they are developing is called HAMMR, or hybrid advanced molecular manufacturing regulator.

“Cancer cells are continually evolving and adapting to therapy. However, currently available diagnostic tools, including radiologic tests, blood assays and biopsies, provide very infrequent and limited snapshots of this dynamic process," Jazaeri adds. "As a result, today’s therapies treat cancer as if it were a static disease. We believe THOR could transform the status quo by providing real-time data from the tumor environment that can in turn guide more effective and tumor-informed novel therapies.”

With a national team of engineers, physicians, and experts across synthetic biology, materials science, immunology, oncology, and more, the team will receive its funding through the Rice Biotech Launch Pad, a newly launched initiative led by Veiseh that exists to help life-saving medical innovation scale quickly.

"Rice is proud to be the recipient of the second major funding award from the ARPA-H, a new funding agency established last year to support research that catalyzes health breakthroughs," Rice President Reginald DesRoches says. "The research Rice bioengineer Omid Veiseh is doing in leading this team is truly groundbreaking and could potentially save hundreds of thousands of lives each year. This is the type of research that makes a significant impact on the world.”

The initial focus of the technology will be on ovarian cancer, and this funding agreement includes a first-phase clinical trial of HAMMR for the treatment of recurrent ovarian cancer that's expected to take place in the fourth year of THOR’s multi-year project.

“The technology is broadly applicable for peritoneal cancers that affect the pancreas, liver, lungs and other organs,” Veiseh says. “The first clinical trial will focus on refractory recurrent ovarian cancer, and the benefit of that is that we have an ongoing trial for ovarian cancer with our encapsulated cytokine ‘drug factory’ technology. We'll be able to build on that experience. We have already demonstrated a unique model to go from concept to clinical trial within five years, and HAMMR is the next iteration of that approach.”

Trending News

 
 

Promoted